摘要
目的 探讨分子靶向治疗（沙利度胺、来那度胺或硼替佐米）对多发性骨髓瘤（MM）患者疗效及生存的影响.方法 回顾性分析217例自1989年至2013年上海交通大学附属第一人民医院血液科收治的MM患者治疗情况,对比不同时期诊治患者的生存情况,分析治疗措施的改进对患者疗效及生存的影响.结果 基于靶向治疗的普及从1998年后开始,1998年之后确诊的MM患者较之前确诊患者的生存期有显著改善.共有75例患者在初始治疗中接受了沙利度胺或硼替佐米治疗,其疗效优于接受MP、VAD等传统方案的患者.在复发、进展阶段中接受靶向治疗的患者有49例,其疗效较传统方案占优.共有16例患者接受了自体或异基因造血干细胞移植,其中接受自体及异基因双移植的有4例,其疗效及生存期较其他未接受移植治疗的患者占优.结论 分子靶向治疗的应用提高了MM的疗效,并进一步使患者的生存时间得到延长.
Objective To investigate the influence of molecular targeted therapy （thalidomide, lenalidomide or bortezomib） on survival and curative effect of patients with multiple myeloma （MM）. Methods The treatment of 217 patients diagnosised as MM from 1998 to 2013 were reviewed. The survival of patients who were diagnosed during different periods were compared, and the impact of improved treatment on the survival and curative effect of patients were analyzed. Results Patients who were recently diagnosed as MM after 1998 had better survival. 75 patients with targeted therapy （thalidomide or bortezomib） for their early treatment had better survival compared to the patients with conventional treatments of MP/VAD. 49 patients with targeted therapy after relapse or progression had a better curative effect than those with conventional treatments. 16 patients had auto-ASCT or allo-SCT, and 4 of them had both auto-ASCT and allo-SCT, who had better survival than patients without transplantation. Conclusion Patients treated with molecular targeted therapy （thalidomide, lenalidomide, bortezomib） had a better curative effect and longer survival.
出处
《白血病．淋巴瘤》
CAS
2014年第2期100-102,106,共4页
Journal of Leukemia & Lymphoma
关键词
多发性骨髓瘤
分子靶向治疗
生存期
生存率
Multiple myeloma
Molecular targeted therapy
Survival time
Survival rate
